 Connection
Diana Medgyesy to Capecitabine
This is a "connection" page, showing publications Diana Medgyesy has written about Capecitabine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.062 |
|
|
|
-
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54.
Score: 0.024
-
Royce ME, Medgyesy D, Zukowski TH, Dwivedy S, Hoff PM, Pazdur R. Colorectal cancer: chemotherapy treatment overview. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):40-6.
Score: 0.010
-
Hoff PM, Royce M, Medgyesy D, Brito R, Pazdur R. Oral fluoropoyrimidines. Semin Oncol. 1999 Dec; 26(6):640-6.
Score: 0.010
-
Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, Pazdur R. Fluoropyrimidines: a critical evaluation. Oncology. 1999 Jul; 57 Suppl 1:2-8.
Score: 0.009
-
Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito R. The oral fluorouracil prodrugs. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):48-51.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|